Terms: = Bone cancer AND SRSF2, Q01130, 6427, SFRS2 AND Treatment
26 results:
1. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract] [Full Text] [Related]
2. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
Versluis J; Saber W; Tsai HK; Gibson CJ; Dillon LW; Mishra A; McGuirk J; Maziarz RT; Westervelt P; Hegde P; Mukherjee D; Martens MJ; Logan B; Horowitz M; Hourigan CS; Nakamura R; Cutler C; Lindsley RC;
J Clin Oncol; 2023 Oct; 41(28):4497-4510. PubMed ID: 37607457
[TBL] [Abstract] [Full Text] [Related]
3. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
[TBL] [Abstract] [Full Text] [Related]
4. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
Klement P; Fiedler W; Gabdoulline R; Dallmann LK; Wienecke CP; Schiller J; Kandziora C; Teich K; Heida B; Büttner K; Brandes M; Funke C; Wichmann M; Othman B; Chromik J; Amberg S; Kebenko M; Schlipfenbacher V; Wilke AC; Modemann F; Janning M; Serve H; Bokemeyer C; Theile S; Deppermann U; Kranich AL; Ganser A; Thol F; Heuser M
Ann Hematol; 2023 Feb; 102(2):323-328. PubMed ID: 36576532
[TBL] [Abstract] [Full Text] [Related]
5. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract] [Full Text] [Related]
6. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract] [Full Text] [Related]
7. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.
Kennedy VE; Perkins C; Reiter A; Jawhar M; Lübke J; Kluin-Nelemans HC; Shomali W; Langford C; Abuel J; Hermine O; Niedoszytko M; Gorska A; Mital A; Bonadonna P; Zanotti R; Tanasi I; Mattsson M; Hagglund H; Triggiani M; Yavuz AS; Panse J; Christen D; Heizmann M; Shoumariyeh K; Müller S; Elena C; Malcovati L; Fiorelli N; Wortmann F; Vucinic V; Brockow K; Fokoloros C; Papageorgiou SG; Breynaert C; Bullens D; Doubek M; Ilerhaus A; Angelova-Fischer I; Solomianyi O; Várkonyi J; Sabato V; Rüfer A; Schug TD; Hermans MAW; Fortina AB; Caroppo F; Bumbea H; Gulen T; Hartmann K; Elberink HO; Schwaab J; Arock M; Valent P; Sperr WR; Gotlib J
Blood Adv; 2023 May; 7(9):1713-1724. PubMed ID: 36094848
[TBL] [Abstract] [Full Text] [Related]
8. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
[TBL] [Abstract] [Full Text] [Related]
9. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract] [Full Text] [Related]
10. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract] [Full Text] [Related]
11. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract] [Full Text] [Related]
12. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract] [Full Text] [Related]
13. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract] [Full Text] [Related]
14. TP-0903 is active in models of drug-resistant acute myeloid leukemia.
Jeon JY; Buelow DR; Garrison DA; Niu M; Eisenmann ED; Huang KM; Zavorka Thomas ME; Weber RH; Whatcott CJ; Warner SL; Orwick SJ; Carmichael B; Stahl E; Brinton LT; Lapalombella R; Blachly JS; Hertlein E; Byrd JC; Bhatnagar B; Baker SD
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33268594
[TBL] [Abstract] [Full Text] [Related]
15. Alteration of SF3B1 and srsf2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract] [Full Text] [Related]
16. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
[TBL] [Abstract] [Full Text] [Related]
17. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract] [Full Text] [Related]
18. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M; Amler S; Goerlich D; Köhnke T; Konstandin NP; Schneider S; Sauerland MC; Herold T; Hubmann M; Ksienzyk B; Zellmeier E; Bohlander SK; Subklewe M; Faldum A; Hiddemann W; Braess J; Spiekermann K; Metzeler KH
Leukemia; 2018 Jul; 32(7):1598-1608. PubMed ID: 29472724
[TBL] [Abstract] [Full Text] [Related]
19. Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis.
Han X; Li W; He N; Feng P; Pang Y; Ji C; Ma D
Clin Chim Acta; 2018 Apr; 479():25-37. PubMed ID: 29309772
[TBL] [Abstract] [Full Text] [Related]
20. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Silver RT; Barel AC; Lascu E; Ritchie EK; Roboz GJ; Christos PJ; Orazi A; Hassane DC; Tam W; Cross NCP
Cancer; 2017 Jul; 123(14):2680-2687. PubMed ID: 28518222
[TBL] [Abstract] [Full Text] [Related]
[Next]